Johnson & Johnson (JNJ)
| Market Cap | 371.55B |
| Revenue (ttm) | 89.33B |
| Net Income (ttm) | 21.81B |
| Shares Out | 2.41B |
| EPS (ttm) | 8.98 |
| PE Ratio | 17.19 |
| Forward PE | 14.64 |
| Dividend | $5.20 (3.37%) |
| Ex-Dividend Date | May 27, 2025 |
| Volume | 5,148,896 |
| Open | 152.02 |
| Previous Close | 154.22 |
| Day's Range | 151.18 - 155.36 |
| 52-Week Range | 140.68 - 169.99 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | 170.40 (+10.35%) |
| Earnings Date | Apr 15, 2025 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $170.4, which is an increase of 10.35% from the latest price.
News
Drugmakers are spared worst-case drug pricing scenario for now
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan.
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Trump says executive order will slash the cost of prescription drugs
President Donald Trump signed an executive order targeting the cost of prescription drugs. Prices will be cut by as much as 80%, and some immediately, he said at a press conference.
Trump Announces Executive Order to Lower Drug Prices
President Donald Trump says he'll sign an executive order that will lower drug prices for Americans. The order aims to align patient costs with lower prices paid abroad, focusing on Medicare and weigh...
White House release details on executive order on drug prices: Here's what to know
CNBC's Eamon Javers reports on the latest news.
Fortress Dividends: 2 Of The Best All-Weather Income Stocks Built To Last
Market turmoil often triggers a rush to 'safe' assets, but I believe these moments are best for buying cyclical stocks with strong upside potential. Rather than chasing what's popular, I focus on all-...
Final Trade: SLV, JNJ, HYG, GOOGL
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Pharma Worries Shift to Prices From Trade. Trump's Next Plan Could Sink Stocks.
The president says big news about drug pricing is coming next week.
J&J's skin disease drug meets main goal in late-stage study
Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal in a late-stage study on patients 12 years and older.
Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demon...
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Jury Orders Johnson & Johnson to Pay $3 Million in Mesothelioma Death of New Orleans Woman
NEW ORLEANS--(BUSINESS WIRE)--A jury has awarded $3 million to the family of Jeanine Henderson, a 72-year-old mother from New Orleans who died from mesothelioma, a rare and incurable cancer caused by ...
Johnson & Johnson expands efforts to champion the nursing workforce globally
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced the expansion of its efforts to champion the nursing workforce and improve access to quality care for communities around the wor...
Dividend Hikes Offer Optimism Amid Tariff Turmoil
Stocks have rebounded sharply off their early-April lows, but macro risks persist. Dividend stocks have largely outperformed so far this year. We profile a pair of blue chips that recently announced d...
3 Stable Stocks to Buy When the Price is Right
There's no such thing as a safe stock, but these low-volatility names stand up relatively well in shaky markets.
Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms
President Donald Trump signed an executive order to incentivize drug manufacturing in the U.S. The order comes ahead of Trump's planned tariffs on pharmaceuticals imported into the U.S.
TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
TREMFYA® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis Findings build on recent FDA-approval of both routes o...
TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years
Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 SAN DIEGO, Calif. ...
Dogs Of The Dow Chase May's 'Safer' Buy
Verizon is the only Dow Dog meeting the ideal of annual dividends from $1K invested exceeding the single share price, supported by adequate free cash flow. Analyst projections suggest top Dow Dogs cou...
Calls of the Day: AutoZone, Roblox, Eli Lilly, Johnson & Johnson and Quanta Services
Oppenheimer upgrades AutoZone — NewEdge Wealth CEO Rob Sechan owns it and breaks it down, while the Investment Committee drops their latest picks.
J&J-backed HistoSonics explores sale at $2.5 billion valuation, FT reports
HistoSonics, a medical technology company backed by Johnson & Johnson , is exploring a potential sale after receiving multiple takeover approaches, the Financial Times reported on Friday, citing peopl...
FDA Approves Johnson & Johnson's IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families
First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older. First and only FcRn blocker approved in anti-AChR and anti-MuSK a...
US FDA approves J&J's immune disorder drug
The U.S. Food and Drug Administration has approved Johnson & Johnson's drug to treat patients aged 12 years and older with an immune-mediated disorder, the drugmaker said on Wednesday.